GMT Capital’s BioLife Solutions BLFS Stock Holding History

GMT Capital’s Portfolio BLFS Stock Details BLFS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-254,007	Closed	-$4.11M	–	84
2019 Q4	$4.11M	Sell	254,007 -2,000	-0.8%	-$32.5K	0.16%	50
2019 Q3	$4.26M	Buy	+256,007	New	+$4.8M	0.16%	60

Other funds holding BLFS

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

SPA

Sentinel Pension Advisors Wakefield, Massachusetts $676M AUM 15.31% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Tarsadia Capital New York $5.64M AUM 15.7% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

SCM

Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return

GMT Capital's BLFS Position: Q1 2020 in Review

GMT Capital sold out of BioLife Solutions (BLFS) in Q1 2020, closing a stake of 254,007 shares — an estimated $4.11M sold.

GMT Capital first reported a position in BLFS in Q3 2019 and held it in 2 quarters. The position peaked at $4.26M in Q3 2019. 75 funds tracked by Wall St. Rank hold BLFS as of Q1 2020.

GMT Capital reported no remaining BioLife Solutions position as of Q1 2020 after selling out during the quarter.
GMT Capital sold 254,007 BioLife Solutions shares in Q1 2020, an estimated $4.11M.
GMT Capital first reported a position in BioLife Solutions in Q3 2019 and held it in 2 quarters.
GMT Capital's BioLife Solutions position peaked at $4.26M in Q3 2019.
75 funds tracked by Wall St. Rank held BioLife Solutions as of Q1 2020.

Based on GMT Capital's 13F filing for Q1 2020, filed 13 May 2020.